FDA considers gene-editing treatment for sickle cell disease

The Food and Drug Administration is set to vote on the use of gene-editing technology to potentially cure sickle cell disease, the painful genetic blood disorder that affects hundreds of thousands of Black, Hispanic, Asian and Middle Eastern Americans. Dr. Bayo Curry-Winchell, medical director at Saint Mary's Urgent Care Group, joined CBS News to discuss the treatment.